Overview

Chordoma is a rare type of bone cancer that starts in the bones of the spine or the skull. Chordomas are different from other bone tumors for reasons including where they grow, how they start and who they affect.

Chordomas can grow anywhere along the spine. But they often grow in two locations. The first is in a bone called the clivus. The clivus is located where the skull sits atop the spine, also called the skull base. The second is at the bottom of the spine, called the sacrum. Chordomas also can grow in the areas in between, sometimes called the mobile spine.

Chordomas start in leftover cells that help form the spine before birth. Usually, any leftover cells go away soon after a baby is born. But sometimes a few of the cells stay. Rarely, in about 1 in 1 million people, the leftover cells eventually become cancerous.

Chordomas can happen at any age. But they most often affect adults ages 40 to 60. Chordomas usually grow slowly. Surgery is usually the main treatment. However, chordomas can be hard to remove fully. This is because they grow very close to the spinal cord, blood vessels, nerves and brain. A chordoma often comes back after treatment.

Types

Different types of chordomas include:

  • Conventional chordoma, also called classic chordoma and classical chordoma. This is the most common type. Under a microscope, it looks like bubbly cells in a slimy mix, similar to soap bubbles.
  • Chondroid chordoma. Up to roughly 15% of chordomas are this type. Under a microscope, chondroid chordomas look similar to classic chordomas. But they also have tissue that looks similar to cartilage tissue found in parts of the body such as the nose.
  • Dedifferentiated. Up to just under 10% of chordomas are this type. Under a microscope, this type of chordoma has two parts. One part looks like classic chordoma cells that also have a special protein called brachyury. The other part looks like a different type of cancer cell.
  • Poorly differentiated. This rare type of chordoma mostly affects kids and young adults and is usually found in the skull base. It's identified due to a missing gene called SMARCB1 (INI1).

Symptoms

Chordoma signs and symptoms may differ depending on where the tumor is located and how large or advanced it is. But no matter where a chordoma is located, symptoms may include:

  • Pain near the location of the tumor.
  • New nerve problems, such as numbness or weakness.
  • New changes to how and when you pass stool or urine.

Skull base chordoma symptoms

The first signs and symptoms of a clival bone chordoma or a skull base chordoma may include:

  • Headache.
  • Facial numbness, weakness, drooping or paralysis.
  • Vision trouble, including blurred or double vision or, sometimes, vision loss.

Other possible symptoms include:

  • Hearing loss.
  • Hoarseness.
  • Trouble speaking as usual.
  • Trouble swallowing.

Middle spine, also called mobile spine, chordoma symptoms

The first signs and symptoms of a chordoma in the part of the spine between the skull base and the sacrum may include:

  • Arm or leg numbness or weakness.
  • Back pain that may spread to the buttocks and legs.
  • Breathing trouble.
  • Headache.
  • Neck stiffness or pain.
  • Neck pain that may spread to the shoulders.
  • Swallowing trouble.
  • Walking trouble.

Bottom of the spine, also called sacral, chordoma symptoms

The first signs and symptoms of a sacral chordoma may include:

  • Constipation.
  • Lump at the site of the tumor.
  • Numbness or tingling in the buttocks and inner thighs.
  • Muscle weakness.
  • Pain in the back, buttocks, pelvis or tailbone that may be worse when sitting.
  • Sudden urge to urinate that's hard to control.

Because chordomas grow very slowly and have general symptoms caused by many things, it's common not to notice signs and symptoms for years.

When to see a doctor

Make an appointment with a doctor or other healthcare professional if you have any symptoms that worry you.

Causes

It's not clear what causes most chordomas. They usually happen randomly. Rarely, they can be hereditary, meaning chordomas can run in families. This cancer most often starts in the bones in the skull or spine.

Chordoma happens when cells in the bones develop changes in their DNA. A cell's DNA holds the instructions that tell the cell what to do. In healthy cells, DNA gives instructions to grow and multiply at a set rate. The instructions tell the cells to die at a set time. In cancer cells, the DNA changes give different instructions. The changes tell the cancer cells to grow and multiply quickly. Cancer cells can keep living when healthy cells would die. This causes too many cells.

The cancer cells form a mass called a tumor. The tumor can grow to invade and destroy healthy body tissue. In time, cancer cells can break away and spread to other parts of the body. Cancer that spreads is called metastatic cancer.

Risk factors

Factors that may increase the risk of chordoma include:

  • Age. Chordoma can happen at any age. Most often, this cancer happens in people ages 40 to 60.
  • Family history. Most chordomas happen randomly. But people with a family history of chordoma may have a greater chance of getting it. When this happens, it's because of changes in certain genes, such as the TBXT gene. This gene plays a role in making a protein called brachyury. Chordomas have a lot of brachyury in them. This can help tell chordomas apart from other tumors.
  • Sex assigned at birth. In adults, people assigned male at birth are somewhat more likely to be diagnosed with chordoma. About 60% of chordomas are found in people assigned male at birth. About 40% of chordomas are found in people assigned female at birth. In children, those assigned female at birth are slightly more likely to be diagnosed with chordoma than are those assigned male at birth.

Complications

Complications of chordomas typically are caused by the tumors growing and pressing into blood vessels, nerves and other tissues. Other complications happen if the cancer spreads to other parts of the body.

Chordoma complications of the nervous system may include:

  • Cerebrospinal fluid leaks, though this is rare.
  • Headaches.
  • Hearing loss.
  • Problems with balance, coordination and walking.
  • Trouble swallowing or speaking.
  • Trouble breathing.
  • Vision problems.
  • Water buildup on the brain, which can increase pressure inside the skull and cause headaches, nausea and vomiting.
  • Weakness or numbness in the face, arms or legs.

Sometimes chordoma tumors can spread to other parts of the body. You may hear this called metastatic chordoma. Less than half of chordomas spread to other parts of the body. It's most common in chordomas that are found in areas of the spine below the neck and with the poorly differentiated type of chordoma. Sometimes metastatic chordoma may be called advanced chordoma or end-stage chordoma.

The most common place for a chordoma to spread is to the lungs. But it also can spread to the liver or other bones or soft tissues. Depending on where metastatic chordoma has spread, complications may include:

  • Bone breaks.
  • Extreme tiredness.
  • Lumps.
  • Pain.
  • Swelling of the belly.
  • Trouble breathing.
  • Yellow skin or eyes, called jaundice.
  • Weight loss.

Oct. 17, 2025

Living with chordoma?

Connect with others like you for support and answers to your questions in the Sarcoma support group on Mayo Clinic Connect, a patient community.

Sarcoma Discussions

worriedgirl35
Possible liposarcoma?

14 Replies Fri, Oct 17, 2025

me67
Undifferentiated Pleomorphic Sarcoma: Anyone else want to share?

132 Replies Thu, Oct 16, 2025

Colleen Young, Connect Director
Diagnosed with sarcoma? Let's share

994 Replies Sat, Sep 27, 2025

See more discussions
  1. Elsevier Point of Care. Clinical Overview: Rare central nervous system tumors. https://www.clinicalkey.com. Accessed Nov. 20, 2024.
  2. Bone cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418. Accessed Aug. 21, 2025.
  3. Winn HR, ed. Youmans and Winn Neurological Surgery. 8th ed. Elsevier; 2023. https://www.clinicalkey.com. Accessed Nov. 20, 2024.
  4. Zenonos GA. Chordoma of the skull base. https://www.uptodate.com/contents/search. Accessed Aug. 21, 2025.
  5. Chordoma. National Cancer Institute. https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-bone-tumors/chordoma. Accessed Aug. 21, 2025.
  6. Barber SM, et al. Chordoma — Current understanding and modern treatment paradigms. Journal of Clinical Medicine. 2021; doi:10.3390/jcm10051054.
  7. Banks C, et al. ICAR: Endoscopic skull-base surgery. International Forum of Allergy & Rhinology. 2019; doi:10.1002/alr.22326.
  8. Stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/stereotactic. Accessed Jan. 29, 2025.
  9. Dickerson TE, et al. Recurrent metastatic chordoma to the liver: A case report and review of the literature. Current Oncology. 2022; doi:10.3390/curroncol29070367.
  10. Song PH, et al. Symptom burden and life challenges reported by adult chordoma patients and their caregivers. Quality of Life Research. 2017; doi:10.1007/s11136-017-1544-2.
  11. Young VA, et al. Clinical study: Characteristics and patterns of metastatic disease from chordoma. Sarcoma. 2015; doi:10.1155/2015/517657.
  12. Alshammari J, et al. Clival chordoma with an atypical presentation: A case report. Journal of Medical Case Reports. 2012; doi:10.1186/1752-1947-6-410.
  13. Dudhe S, et al. Challenging the giant: A case report on a huge sacrococcygeal chordoma and its radiological insights. Radiology Case Reports. 2025; doi:10.1016/j.radcr.2024.10.157.
  14. Zhou Y, et al. The clinical outcomes for chordomas in the cranial base and spine: A single center experience. Medicine. 2019; doi:10.1097/MD.0000000000015980.
  15. Medical oncologic treatment of spinal malignancies and outcomes. Video. Mayo Clinic; 2023.
  16. Murphey MD, et al. Imaging of spinal chordoma and benign notochordal cell tumor (BNCT) with radiologic pathologic correlation. Skeletal Radiology. 2023; doi:10.1007/s00256-022-04158-7.
  17. Baig Mirza A, et al. Surgical management of spinal chordoma: A systematic review and single-center experience. World Neurosurgery. 2021; doi:10.1016/j.wneu.2021.09.001.
  18. Court C, et al. Management of chordoma of the sacrum and mobile spine. Orthopaedics & Traumatology: Surgery & Research. 2022; doi:10.1016/j.otsr.2021.103169.
  19. Goumenos S, et al. Clinical outcome after surgical treatment of sacral chordomas: A single-center retrospective cohort of 27 patients. Cancers. 2024; doi:10.3390/cancers16050973.
  20. Garofalo F, et al. The unresolved case of sacral chordoma: From misdiagnosis to challenging surgery and medical therapy resistance. Annals of Coloproctology. 2014; doi:10.3393/ac.2014.30.3.122.
  21. Zhang J, et al. Intradural cervical chordoma with diffuse spinal leptomeningeal spread: Case report and review of the literature. European Spine Journal. 2018; doi:10.1007/s00586-017-5443-6.
  22. Passeri T, et al. The mutational landscape of skull base and spinal chordomas and the identification of potential prognostic and theranostic biomarkers. Journal of Neurosurgery. 2023; doi:10.3171/2023.1.JNS222180.
  23. Ma T, et al. Current understanding of brachyury in chordoma. BBA — Reviews on Cancer. 2023; doi:10.1016/j.bbcan.2023.189010.
  24. Elsamadicy AA, et al. The association of gender in the management and prognosis of vertebral and sacral chordoma: A SEER analysis. Journal of Clinical Medicine. 2025; doi:10.3390/jcm14051737.
  25. What is cancer? American Cancer Society. https://www.cancer.org/cancer/understanding-cancer/what-is-cancer.html. Accessed Aug. 31, 2025.
  26. Soule E, et al. Current management and image review of skull base chordoma: What the radiologist needs to know. 2021; doi:10.25259/JCIS_139_2021.
  27. CT scan. Mayo Clinic. https://www.mayoclinic.org/tests-procedures/ct-scan/about/pac-20393675. Accessed Sept. 4, 2025.
  28. American College of Surgeons. Bone cancer. In: AJCC Cancer Staging System. American College of Surgeons; 2025. https://online.statref.com. Accessed Sept. 8, 2025.
  29. Dastgheyb SS, et al. A prospective phase I/II clinical trial of high-dose proton therapy for chordomas and chondrosarcomas. Advances in Radiation Oncology. 2024; doi:10.1016/j.adro.2024.101456.
  30. Childhood chordoma treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/bone/hp/child-chordoma-treatment-pdq. Accessed Sept. 9, 2025.
  31. Immunotherapy. American Cancer Society. https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html. Accessed Sept. 18, 2025.
  32. Shyam Sunder S, et al. Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy. 2023; doi:10.1038/s41392-023-01469-6.
  33. Cancer survival rate: What it means for your prognosis. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer/art-20044517. Accessed Sept. 18, 2025.
  34. Cancer survivors: Care for your body after treatment. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer-survivor/art-20044015. Accessed Sept. 18, 2025.
  35. Stacchioti S, et al. Best practices for the management of local-regional recurrent chordoma: A position paper by the Chordoma Global Consensus Group. Annals of Oncology. 2017; doi:10.1093/annonc/mdx05.
  36. Bone cancer. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/bone-cancer/symptoms-causes/syc-20350217. Accessed Sept. 11, 2025.
  37. Steffner RJ, et al. Staging of bone and soft-tissue sarcomas. Journal of the American Academy of Orthopedic Surgeons. 2018; doi:10.5435/JAAOS-D-17-00055.
  38. Terminal cancer. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/terminal-cancer. Accessed Sept 12, 2025.
  39. Cancer pain: Relief is possible. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer-pain/art-20045118. Accessed Sept. 18, 2025.
  40. Health Education & Content Services. Chordoma overview. Mayo Clinic; 2025.
  41. Sahgal A, et al. Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: Preliminary outcomes. Neuro-Oncology. 2015; doi:10.1093/neuonc/nou347.
  42. Chhabra AM, et al. Proton therapy for spinal tumors: A consensus statement from the Particle Therapy Cooperative Group. International Journal of Radiation Oncology, Biology, Physics. 2024; doi:10.1016/j.ijrobp.2024.04.007.
  43. Maroufi SF, et al. Stereotactic radiosurgery in the management of skull base chordomas: A comprehensive systematic review and meta-analysis. Neurosurgical Focus. 2024; doi:10.3171/2024.2.FOCUS249.
  44. Ghaith, AK, et al. Impact of proton versus photon radiotherapy on overall survival in the management of spinal chordoma and mortality risk prediction: A nationwide analysis. Journal of Neuro-Oncology. 2025; doi:10.1007/s11060-025-05104-y.
  45. Myneni, S, et al. Exploring perspectives on skull base chordoma management: A modified Delphi approach to consensus. Journal of Neuro-Oncology. 2025; doi:10.1007/s11060-025-05088-9.
  46. Han Y, et al. Clinical differences among histological categories of sarcoma: Insights from 97,062 patients. Cancers (Basel). 2025; doi:10.3390/cancers17101706.
  47. Rodrigues ACLF, et al. Proton beam and carbon ion radiotherapy in skull base chordoma: A systematic review, meta-analysis and meta-regression with trial sequential analysis. Neurosurgical Review. 2024; doi:10.1007/s10143-024-03117-1.

Related

Associated Procedures

Products & Services